Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Management paradigms for metastatic castration-sensitive prostate cancer

How does the clinician use quality of life data to decide between chemotherapy and hormonal therapy?


16 Oct 2020


Management paradigms for metastatic castration-sensitive prostate cancer


Cytotoxic Therapy

Tumour Site

Prostate Cancer


Alicia Morgans


A.K. Morgans

Author affiliations

  • Medicine, Northwestern University Feinberg School of Medicine, 60611 - Chicago/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.